CWEB

Groupon Still The King of Daily Deals - CWEB.com By: Leslie Cohen Managing Editor Strong growth in and platform initiatives raises full year 2018 adjusted ebitda outlook gross profit of $324.9 million net loss from continuing operations of $2.8 million adjusted ebitda of $52.6 million gaap loss per diluted share of $0.01. 61.90% of Groupon Shares are owned by institutional investors. Strong institutional ownership indicates big money managers and hedge funds believe that a company is poised for long-term growth.  The number of shares currently selling short amount to 8.6% of shares outstanding with an uptick of 3.23% last month. Groupon is down 6.08 this year, but Wall Street is bullish on the stock. The analysts that cover Groupon have a buy equivalent rating on it.  Analysts are suggesting a 17-point percentage game recent close. Vanguard Group Inc., which owns 34,432,805 shares of the stock are valued at $159.77 million.   The third l...

Can CVS Health Buy BioPharmX Corporation? - CWEB.com Corporate health-care deal value surged 37 percent last year, according to a new report from consulting firm Bain & Company. The number of health-care mergers and acquisitions rose 16 percent. CVS Health's planned acquisition of health insurer Aetna was the largest corporate deal of 2017 at $69 billion. The health-care shopping spree isn't likely to stop anytime soon. Corporate deal value surged to $332 billion last year, up 27 percent from $261 billion in 2016, though still below the peak of $432 billion in 2015, according to a  new report  from consulting firm Bain & Company. What does make BioPharmX unique? Financial Health : Does it have a healthy balance sheet? Management :Have insiders been ramping up their shares to take advantage of the market’s sentiment for BPMX’s future outlook? Other High-Growth Alternatives : BPMX is a high-growth stock you could be holding? Walgreens  was also...

Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX – CWEB.com Institutional investors currently hold major shares in BioPharmX Corporation( BPMX ) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018 BioPharmX Corporation ( BPMX ) stock was most active stock of Wall Street Market on Tuesday. BPMX moved -1.77% to 0.19. BPMX received interesting focus from Active Investors and it has been trading on front line as seeing to it recent volume. Statistic show the size of the acne treatment market worldwide in 2016 and a forecast for 2025, in billion U.S. dollars. In 2016, the global acne treatment market was worth some 4.9 billion dollars and was expected to grow to over 7 billion by the end of 2025. Statistic also show the market value of skincare products in Great Britain from 2009 to 2016. The total value of the skincare market in December 2016 was measured at approximately 2.16 bill...

BioPharmX Corporation ( BPMX ) is a dermatology focused clinical stage pharmaceutical. BioPharmX Corporation  ( BPMX ) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. Institutions own 28.93% of BioPharmX Corporation ( BPMX ) ’s shares. Among active positions in the latest quarter, 7 holders increased their positions by a total of 10.8 million shares. This works out to a net increase in ownership of 9.61 million shares, and suggests that institutions are feeling bullish about the stock. Sabby Management LLC purchased a new stake in Biopharmx Corp ( BPMX )during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 6,713,756 shares of the...

California STD's Raging At All Time Highs And Akers Biosciences Is Working On It - CWEB.com According to NPR  https://www.npr.org/sections/thetwo-way/2018/05/15/611307046/california-stds-raging-at-all-time-highs-for-third-year-in-a-row The La Times  http://www.latimes.com/local/california/la-me-ln-std-rates-20180515-story.html and CBS News  https://www.cbsnews.com/news/std-cases-reach-all-time-high-in-california-report-finds/ California STD cases have reached all time high.  More than 300,000 cases of chlamydia, gonorrhea and syphilis were reported in 2017, a 45 percent increase from five years ago, according to data released by the California Department of Public Health.  Dr. Heidi Bauer, chief of the state health department's STD Control Branch, agreed that budget issues are part of the problem. She estimated that about $20 million in state and federal money is allocated yearly to fighting STDs — a small number in a state with nearly 40 mi...